View clinical trials related to Malignant Neoplasms.
Filter by:Paclitaxel covered metal biliary stent is non-inferior to common covered metal biliary stent in their patency rate and safety at the 6 months after stenting.
Background: - Studies suggest that cancer patients diagnosed and treated in a facility with multi-specialty care and clinical research may live longer and have a better quality of life than patients treated elsewhere. - The NCI Community Cancer Centers Pilot Program (NCCCP) is a 3-year program to test the concept of a national network of community cancer centers to expand cancer research and deliver the most advanced cancer care to Americans in their own communities. - The pilot program includes a survey of cancer patients receiving care at the pilot sites. Objectives: - To gain an understanding of the experiences of adult patients who receive services at the NCCCP pilot sites and assess if and how their experience changes over the study period. Data about the following are collected: - Patients information needs and awareness of the NCCCP program - Clinical trials experience - Access to health care - Perspectives on patient-provider communication - Experiences with patient navigation, self-management, medical decision-making and survivorship - Satisfaction with care and quality of life Eligibility: - Patients 21 years or older at the time of diagnosis - Treatment at the cancer center for at least 3 months since July 1, 2007 Design: - Participants complete a 25-minute questionnaire covering the care they received at their cancer center, their experience with making medical appointments and how long they waited to see the doctor. The survey includes information on the following: - Services at the cancer center - Getting needed care - Assistance for patients and their families - Communication with the cancer care team - Clinical trials - Care after finishing treatment - Evaluation of care - Health and medical history - Background information (demographics)
Selected patients suspected of having or with prior biopsy proof of malignant disease will be seen in the Urologic Oncology Branch, NCI. Blood samples may be collected at the time of the initial visit and at periodic intervals during the course of the disease. These samples will be stored in the tissue bank of the Urologic Oncology Branch. Aliquots of malignant and normal tissue will be collected at the time of surgery and stored in the tissue bank, Urologic Oncology Branch, NCI. These materials will be used in the research efforts of the Urologic Oncology Branch, NCI....